Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2019 3
2020 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Staber PB, et al. Among authors: kadia tm. Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Blood. 2019. PMID: 31292114 Free PMC article. Review.
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Borthakur G, et al. Among authors: kadia tm. Am J Hematol. 2014 Oct;89(10):964-8. doi: 10.1002/ajh.23795. Epub 2014 Jul 21. Am J Hematol. 2014. PMID: 24990142 Free PMC article.
Which FLT3 Inhibitor for Treatment of AML?
Senapati J, Kadia TM. Senapati J, et al. Among authors: kadia tm. Curr Treat Options Oncol. 2022 Mar;23(3):359-380. doi: 10.1007/s11864-022-00952-6. Epub 2022 Mar 8. Curr Treat Options Oncol. 2022. PMID: 35258791 Review.
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R, Piérola AA, Donnellan WB, Yordi AM, Abdul-Hay M, Platzbecker U, Subklewe M, Kadia TM, Alonso-Domínguez JM, McCloskey J, Bradford K, Curtis M, Daskalakis N, Guttke C, Safer K, Hiebert B, Murphy J, Li X, Duchin K, Esteban D. Narayan R, et al. Among authors: kadia tm. Clin Transl Sci. 2024 Mar;17(3):e13742. doi: 10.1111/cts.13742. Clin Transl Sci. 2024. PMID: 38494922 Free PMC article. Clinical Trial.